Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133309) titled 'Efficacy and Survival Outcomes of Glofitamab in Central Nervous System Lymphoma: A Retrospective Study' on Sept. 24.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Huashan Hospital, Fudan University
Condition:
Primary Central Nervous System Lymphoma
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-05-26
Target Sample Size: Observation group:20;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=336654
Published by HT Digital Content Services with permission from Health Daily Digest....